Literature DB >> 15860672

Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.

Mitsufumi Nishio1, Tomoyuki Endo, Nobuhiro Tsukada, Junko Ohata, Shinichi Kitada, John C Reed, Nathan J Zvaifler, Thomas J Kipps.   

Abstract

We examined expression of B cell-activating factor of the tumor necrosis factor (TNF) family (BAFF) and a proliferation-inducing ligand (APRIL) on chronic lymphocytic leukemia (CLL) B cells and nurselike cells (NLCs), which differentiate from CD14+ cells when cultured with CLL B cells. NLCs expressed significantly higher levels of APRIL than monocytes and significantly higher levels of BAFF and APRIL than CLL B cells. Also, the viability of CLL B cells cultured with NLCs was significantly reduced when CLL B cells were cultured with decoy receptor of B-cell maturation antigen (BCMA), which can bind both BAFF and APRIL, but not with BAFF receptor:Fc (BAFF-R:Fc), which binds only to BAFF. The effect(s) of BAFF or APRIL on leukemia cell survival appeared additive and distinct from that of stromal cell-derived factor-1alpha (SDF-1alpha), which in contrast to BAFF or APRIL induced leukemia cell phosphorylation of p44/42 mitogen-activated protein kinase (extracellular signal-regulated kinase-1/2 [ERK1/2]) and AKT. Conversely, BAFF and APRIL, but not SDF-1alpha, induced CLL-cell activation of the nuclear factor-kappaB1 (NF-kappaB1) and enhanced CLL-cell expression of the antiapoptotic protein Mcl-1. However, BAFF, but not APRIL, also induced CLL-cell activation of NF-kappaB2. We conclude that BAFF and APRIL from NLCs can function in a paracrine manner to support leukemia cell survival via mechanisms that are distinct from those of SDF-1alpha, indicating that NLCs use multiple distinct pathways to support CLL-cell survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860672      PMCID: PMC1895149          DOI: 10.1182/blood-2004-03-0889

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  58 in total

1.  Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells.

Authors:  L Lagneaux; A Delforge; C De Bruyn; M Bernier; D Bron
Journal:  Leuk Lymphoma       Date:  1999-11

2.  Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

Authors:  J A Burger; N Tsukada; M Burger; N J Zvaifler; M Dell'Aquila; T J Kipps
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

3.  CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival.

Authors:  Silvia Deaglio; Tiziana Vaisitti; Luciana Bergui; Lisa Bonello; Alberto L Horenstein; Luca Tamagnone; Laurence Boumsell; Fabio Malavasi
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

4.  Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

Authors:  J A Burger; M Burger; T J Kipps
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

5.  The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6.

Authors:  M L Kuo; S E Chuang; M T Lin; S Y Yang
Journal:  Oncogene       Date:  2001-02-08       Impact factor: 9.867

6.  MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells.

Authors:  M J Boucher; J Morisset; P H Vachon; J C Reed; J Lainé; N Rivard
Journal:  J Cell Biochem       Date:  2000-09-07       Impact factor: 4.429

7.  Distinct roles for extracellular-signal-regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis.

Authors:  K M Schubert; V Duronio
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

8.  Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.

Authors:  S A Marsters; M Yan; R M Pitti; P E Haas; V M Dixit; A Ashkenazi
Journal:  Curr Biol       Date:  2000-06-29       Impact factor: 10.834

9.  Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis.

Authors:  M Majka; A Janowska-Wieczorek; J Ratajczak; M A Kowalska; G Vilaire; Z K Pan; M Honczarenko; L A Marquez; M Poncz; M Z Ratajczak
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

10.  IkappaB kinase alpha is essential for mature B cell development and function.

Authors:  T Kaisho; K Takeda; T Tsujimura; T Kawai; F Nomura; N Terada; S Akira
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  94 in total

Review 1.  Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.

Authors:  Wan Zhang; Peng Huang
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

2.  Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Authors:  Davorka Messmer; Jessie-F Fecteau; Morgan O'Hayre; Ila S Bharati; Tracy M Handel; Thomas J Kipps
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

Review 3.  [Tumor-associated macrophages: Function and differentiation].

Authors:  G Niedobitek; M H Barros; J H Dreyer; F Hauck; D Al-Sheikhyaqoob
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

4.  Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.

Authors:  Ting Song; Gaobo Chai; Yubo Liu; Xiaoyan Yu; Ziqian Wang; Zhichao Zhang
Journal:  Br J Pharmacol       Date:  2016-01-16       Impact factor: 8.739

Review 5.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

6.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

7.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

8.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

9.  Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Charalampos Pontikoglou; Maria-Christina Kastrinaki; Mirjam Klaus; Christina Kalpadakis; Pavlos Katonis; Kalliopi Alpantaki; Gerassimos A Pangalis; Helen A Papadaki
Journal:  Stem Cells Dev       Date:  2013-02-01       Impact factor: 3.272

10.  Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Li Jia; Andrew Clear; Feng-Ting Liu; Janet Matthews; Nadiha Uddin; Aine McCarthy; Elena Hoxha; Catherine Durance; Sameena Iqbal; John G Gribben
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.